Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALAFOSS-01: AZD0022 in KRAS G12D-mutated solid tumours
jRCT2031240552Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of AZD0022 in non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) and colorectal cancer (CRC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence of adverse events (AEs) and serious adverse events (SAEs) and 2 more. Started Jan 2024; status: completed.
02
Drugs
AZD0022
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031240552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240552.